VivoSeq
Other

R/R NHL

0

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

R/R NHL is an early-stage landscape with 0 programs across 1 company. The most active players are IGM Biosciences, Inc..

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

0/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

IGM Biosciences, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

4

clinical trials

Recruiting1 · 25%
Terminated1 · 25%
No longer available1 · 25%
Unknown status1 · 25%

Clinical Trials

Trial Activity

Linperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07195799·180 enrolled
Study of LUCAR-20S in Patients With R/R NHL
Terminated·TThe First Affiliated Hospital with Nanjing Medical University·Phase 1·NCT04176913·7 enrolled
Expanded Access of Imvotamab (IGM-2323) in Patients With R/R NHL
No longer available·IIGM Biosciences, Inc.·N/A·NCT06331832
MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin
Unknown status·GGC Cell Corporation·Phase 1/2·NCT03778619·9 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)